MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329639 | Name: BMOV

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMOV, also known as Bis(maltolato)oxovanadium(IV) is a Potent insulin mimetic. Bis(maltolato)oxovanadium(IV) normalizes glucose and lipid values and restores food and fluid intake to control levels in diabetic rats without increasing insulin levels (0.37 mmol/kg). It attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Its mechanism of action includes inhibition of PTP1B as well as other tyrosine phosphatases. The drug is nontoxic in vitro at useful concentrations and displays no signs of toxicity in mice at high oral doses.

Chemical Structure

BMOV
BMOV
CAS#38213-69-3

Theoretical Analysis

MedKoo Cat#: 329639

Name: BMOV

CAS#: 38213-69-3

Chemical Formula: C12H10O7V

Exact Mass: 316.9866

Molecular Weight: 317.15

Elemental Analysis: C, 45.45; H, 3.18; O, 35.31; V, 16.06

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Bis(maltolato)oxovanadium(IV), BMOV
IUPAC/Chemical Name
2-methyl-3-((((2-methyl-4-oxo-4H-pyran-3-yl)oxy)(oxo)vanadio)oxy)-4H-pyran-4-one
InChi Key
XUOLEICXAPEOSI-UHFFFAOYSA-L
InChi Code
InChI=1S/2C6H6O3.O.V/c2*1-4-6(8)5(7)2-3-9-4;;/h2*2-3,8H,1H3;;/q;;;+2/p-2
SMILES Code
O=C1C(O[V](OC2=C(C)OC=CC2=O)=O)=C(C)OC=C1
Appearance
Black solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 317.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Willsky GR, Goldfine AB, Kostyniak PJ, McNeill JH, Yang LQ, Khan HR, Crans DC. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV). J Inorg Biochem. 2001 May;85(1):33-42. PubMed PMID: 11377693. 2: Liu JC, Yu Y, Wang G, Wang K, Yang XG. Bis(acetylacetonato)-oxovanadium(iv), bis(maltolato)-oxovanadium(iv) and sodium metavanadate induce antilipolytic effects by regulating hormone-sensitive lipase and perilipin via activation of Akt. Metallomics. 2013 Jun;5(7):813-20. doi: 10.1039/c3mt00001j. PubMed PMID: 23576171. 3: Sánchez-González C, Rivas-García L, López-Chaves C, Rodríguez-Nogales A, Algieri F, Gálvez J, Gómez-Aracena J, Vera-Ramírez L, Montes-Bayon M, Sanz-Medel A, Llopis J. Exposure to bis(maltolato)oxovanadium(IV) increases levels of hepcidin mRNA and impairs the homeostasis of iron but not that of manganese. Food Chem Toxicol. 2014 Nov;73:113-8. doi: 10.1016/j.fct.2014.08.011. Epub 2014 Aug 25. PubMed PMID: 25168077. 4: Jindal S, Singh M, Balakumar P. Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int J Cardiol. 2008 Aug 29;128(3):383-91. Epub 2007 Jul 20. PubMed PMID: 17658639. 5: Yuen VG, Bhanot S, Battell ML, Orvig C, McNeill JH. Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats. Can J Physiol Pharmacol. 2003 Nov;81(11):1049-55. PubMed PMID: 14719040. 6: Shukla R, Barve V, Padhye S, Bhonde R. Synthesis, structural properties and insulin-enhancing potential of bis(quercetinato)oxovanadium(IV) conjugate. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4961-5. PubMed PMID: 15341960. 7: Peters KG, Davis MG, Howard BW, Pokross M, Rastogi V, Diven C, Greis KD, Eby-Wilkens E, Maier M, Evdokimov A, Soper S, Genbauffe F. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J Inorg Biochem. 2003 Aug 1;96(2-3):321-30. PubMed PMID: 12888267. 8: Parajón-Costa BS, Baran EJ. Vibrational spectra of bis(maltolato)oxovanadium(IV): a potent insulin mimetic agent. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Jan;78(1):133-5. doi: 10.1016/j.saa.2010.09.010. Epub 2010 Sep 17. PubMed PMID: 20934377. 9: Sánchez-González C, López-Chaves C, Trenzado CE, Aranda P, López-Jurado M, Gómez-Aracena J, Montes-Bayón M, Sanz-Medel A, Llopis J. Changes in iron metabolism and oxidative status in STZ-induced diabetic rats treated with bis(maltolato) oxovanadium (IV) as an antidiabetic agent. ScientificWorldJournal. 2014 Jan 5;2014:706074. doi: 10.1155/2014/706074. eCollection 2014. PubMed PMID: 24511298; PubMed Central PMCID: PMC3913100. 10: Sanna D, Bíró L, Buglyó P, Micera G, Garribba E. Biotransformation of BMOV in the presence of blood serum proteins. Metallomics. 2012 Jan;4(1):33-6. doi: 10.1039/c1mt00161b. Epub 2011 Nov 17. PubMed PMID: 22094980. 11: Yuen VG, Pederson RA, Dai S, Orvig C, McNeill JH. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. Can J Physiol Pharmacol. 1996 Sep;74(9):1001-9. PubMed PMID: 8960391. 12: Wei YB, Yang XD. Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex. Biometals. 2012 Dec;25(6):1261-8. doi: 10.1007/s10534-012-9587-x. Epub 2012 Sep 27. PubMed PMID: 23015214. 13: Sanchez-Gonzalez C, Bermudez-Peña C, Guerrero-Romero F, Trenzado CE, Montes-Bayon M, Sanz-Medel A, Llopis J. Effect of bis(maltolato)oxovanadium (IV) (BMOV) on selenium nutritional status in diabetic streptozotocin rats. Br J Nutr. 2012 Sep;108(5):893-9. doi: 10.1017/S0007114511006131. Epub 2011 Nov 16. PubMed PMID: 22085676. 14: Mustafi D, Makinen MW. Structure and conformation of bis(acetylacetonato)oxovanadium(IV) and bis(maltolato)oxovanadium(IV) in solution determined by electron nuclear double resonance spectroscopy. Inorg Chem. 2005 Aug 8;44(16):5580-90. PubMed PMID: 16060607. 15: Winter PW, Al-Qatati A, Wolf-Ringwall AL, Schoeberl S, Chatterjee PB, Barisas BG, Roess DA, Crans DC. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains. Dalton Trans. 2012 Jun 7;41(21):6419-30. doi: 10.1039/c2dt30521f. Epub 2012 Apr 30. PubMed PMID: 22569684. 16: Nischwitz V, Davies JT, Marshall D, González M, Gómez Ariza JL, Goenaga-Infante H. Speciation studies of vanadium in human liver (HepG2) cells after in vitro exposure to bis(maltolato)oxovanadium(IV) using HPLC online with elemental and molecular mass spectrometry. Metallomics. 2013 Dec;5(12):1685-97. doi: 10.1039/c3mt00143a. Epub 2013 Oct 18. PubMed PMID: 24136403. 17: Iglesias-González T, Sánchez-González C, Montes-Bayón M, Llopis-González J, Sanz-Medel A. Absorption, transport and insulin-mimetic properties of bis(maltolato)oxovanadium (IV) in streptozotocin-induced hyperglycemic rats by integrated mass spectrometric techniques. Anal Bioanal Chem. 2012 Jan;402(1):277-85. doi: 10.1007/s00216-011-5286-7. Epub 2011 Aug 13. PubMed PMID: 21842199. 18: Wei Y, Zhang C, Zhao P, Yang X, Wang K. A new salicylic acid-derivatized kojic acid vanadyl complex: synthesis, characterization and anti-diabetic therapeutic potential. J Inorg Biochem. 2011 Aug;105(8):1081-5. doi: 10.1016/j.jinorgbio.2011.05.008. Epub 2011 May 27. PubMed PMID: 21726771. 19: Vardatsikos G, Mehdi MZ, Srivastava AK. Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses (review). Int J Mol Med. 2009 Sep;24(3):303-9. Review. PubMed PMID: 19639221. 20: Bordbar AK, Creagh AL, Mohammadi F, Haynes CA, Orvig C. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin. J Inorg Biochem. 2009 Apr;103(4):643-7. doi: 10.1016/j.jinorgbio.2008.10.009. Epub 2008 Oct 17. PubMed PMID: 19056126.

View History

Quinifur

Quinifur